HealthLinx Inks Deals for Prostate Cancer Biomarkers, Ovarian Cancer Dx | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – HealthLinx separately announced this month a collaboration with the Garvan Institute of Medical Research to assess HealthLinx's IP for prostate cancer, and the appointment of CPC Clinical Research to aid it in obtaining approval from US regulators for its ovarian cancer test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.